Rohto Pharmaceutical Co., Ltd.

Five shareholders are currently on record for Rohto Pharmaceutical Co., Ltd., reflecting the kabunushi meibo (shareholder register) maintained under Articles 121-122 of the Companies Act rather than a public filing. The largest of these is VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund, holding 6.6% — the largest recorded stake — followed by iShares Core MSCI EAFE ETF at 2.5%; the remaining 3 shareholders shown hold smaller stakes. Because every shareholder shown is a company rather than an individual, the ownership chain continues above this level, and no beneficial owner can be established from this filing alone.

Every shareholder recorded for Rohto Pharmaceutical Co., Ltd. is itself a company rather than a natural person, so no Ultimate Beneficial Owner (UBO) is identified at this level; establishing one would require tracing the ownership of each shareholding company in turn.

5 shareholders are shown on record for Rohto Pharmaceutical Co., Ltd.. The register reports 19 in total; only the top 5 by holding are shown here.

Rohto Pharmaceutical Co., Ltd.'s registration number is 6120001019253, filed with National Tax Agency — Corporate Number Publication Site in Japan. Its current status on the register is active.

Rohto Pharmaceutical Co., Ltd.'s status on National Tax Agency — Corporate Number Publication Site is listed as active.

Rohto Pharmaceutical Co., Ltd. was incorporated on 5 October 2015, according to National Tax Agency — Corporate Number Publication Site.

The registered address on file for Rohto Pharmaceutical Co., Ltd. is Ikuno Ward, Osaka City, Japan.

Rohto Pharmaceutical Co., Ltd. is registered as a Private limited company (Ltd.) in Japan.

The Chief Communication Officer & Director of Rohto Pharmaceutical Co., Ltd. on record is Yoshie Ohkouchi; 5 officers are shown here, filed with National Tax Agency — Corporate Number Publication Site. Management authority at Rohto Pharmaceutical Co., Ltd. sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.

Rohto Pharmaceutical Co., Ltd. has no recorded parent company — it sits at the top of its own group structure, with 25 subsidiaries recorded beneath it across 11 jurisdictions. Those 25 subsidiaries span Japan, Vietnam, Brazil, Indonesia, China, Hong Kong, and 5 more jurisdictions, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear. Two of the 25 go a level deeper still, with their own further subsidiaries recorded beneath them — additional ownership layers this view doesn't expand.

This profile reflects a point-in-time snapshot from National Tax Agency — Corporate Number Publication Site. Zavia's monitoring API can track changes to Rohto Pharmaceutical Co., Ltd.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.

Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Japan, so records like Rohto Pharmaceutical Co., Ltd.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.

This record is sourced directly from National Tax Agency — Corporate Number Publication Site and was last synced on 22 September 2026.